Shire links with Boston Children's Hospital for pediatric rare disease research

Ireland-headquartered Shire (LSE: SHP) has entered into a three-year, broad research collaboration in rare diseases with the Boston Children's Hospital. The goal of the collaboration is to develop novel therapies to treat a number of rare pediatric diseases with high unmet medical need, thereby leveraging Boston Children's research expertise and Shire's development and commercialization capabilities.

Under the terms of the accord, Shire will make an initial, undisclosed, upfront payment to Boston Children's and will have the opportunity to fund selected research programs. The emphasis will be on opportunities that have the potential to deliver a development candidate in less than three years from project initiation.

Shire’s options and responsibilities